Second compassionate use program of ParvOryx in combination with an immune checkpoint inhibitor alone (1) or in combination with Avastin(R) and an immune checkpoint inhibitor (8) without prior surgery

Trial Profile

Second compassionate use program of ParvOryx in combination with an immune checkpoint inhibitor alone (1) or in combination with Avastin(R) and an immune checkpoint inhibitor (8) without prior surgery

Active, no longer recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs H 1PV (Primary) ; Bevacizumab
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jun 2017 Subjects are assumed as an adult patients and gender as male & female.
    • 01 Jun 2017 New trial record
    • 23 May 2017 Preliminary results published in an Oryx GmbH & Co Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top